Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Blog
Blog Library
BioSci Deal of the Month - Kainos Medicines & Emmaus Life Sciences
In February of 2021, Emmaus Life Sciences and Kainos Medicine entered into an agreement to jointly develop Kainos’ patented IRAK4 inhibitor (KM10544).
Podcast: A new audio formulation for our PD(L)anner
Our PD(L)anner reports are now hitting the airwaves.
Meet the Evaluate Team: Lisa Urquhart
In this edition of Meet the Team, we’re chatting to someone who is bordering on national treasure territory. Lisa Urquhart is the editor of Evaluate Vantage where she…
It’s all about impact: why orphan drugs are a big deal for patients and pipelines
300 million people worldwide are living with a rare disease. The "orphan" drugs created to treat them have been a fast-growing part of the pharma market for…
Meet the Evaluate Team: Tom Moore
It’s Meet the Team time again and to kick off 2023 we’re hopping across the pond to meet one of our US-based team members, Tom Moore, SVP Account Management - Americas.…
In case you missed it: Three things we learned from the Evaluate Vantage 2023 Preview webinar
Missed out latest webinar? Fear not, here are three things we learned from the 2023 Preview discussion. And the webinar is available on demand now.
PODCAST: Significant catalysts on the horizon
Got 10 minutes? Grab a coffee and listen to our latest podcast diving into some of the big oncology catalysts we’ll be looking out for.
More in hope than expectation: Biopharma in 2023
Few people are expecting biopharma to stage a spectacular comeback in 2023 but what can we reasonably hope for - and when?
Machine Learning and Intelligent Forecasting: Beyond the Black Box
The black box. That mysterious widget in which myriad magic tricks reside. For some it is a magical force that delivers exactly what you need, even if you don’t entirely…
What to expect from JP Morgan 2023
The real start to the biopharma year, the JP Morgan Healthcare Conference, is nearly upon us. As the holidays fade into memory – along with a pretty rough 2022 – what…